Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the United States, Europe, and internationally. The company was incorporated in 2021 and is headquartered in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc.…
Picard Medical Reports Third Quarter 2026 Financial Results; Gross Profit Positive for Third Consecutive Quarter; Net Loss Narrows 79% to $2.2 Million
Picard Medical (NYSEAMERICAN: PMI) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 75 employees.
The shares were at 6.790 USD on 20 November 2026, down 94.3% over 52 weeks. Its 52-week range is 2.652 USD to 208.00 USD: the price is 96.7% below the high and 156.0% above the low.
At a market capitalisation of 18.07M USD, it trades at 3.0 times trailing earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 88% for PMI.
Picard Medical reports an operating margin of -267.2% and revenue down 81.7% year over year.
Its debt exceeds its cash by 2.58M USD, a debt-to-equity ratio of 1.84. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.